Arrowhead Pharmaceuticals, Inc.(ARWR)NASDAQ
Stock Overview & Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) quick overview 2026-02-20
- The stock is currently trading at $63.59, experiencing a short-term pullback within a larger uptrend—trading below its 50-day average while holding above the 200-day.
- Analysts appear optimistic, with a 1-year price target of $81.36 (27.9% upside).
- Volatility is elevated (37.71% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (104.61% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Arrowhead Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $8.79B
P/E Ratio
Forward P/E: -14.85
Revenue Growth
Year over Year
Analyst Target
+27.9% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Neutral (RSI 43.78)
- Fundamentals say: Caution warranted (high leverage concerns)
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $698.16M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
Trading Range
Over the past year, the stock traded between $9.57 and $76.76—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 37.71% annualized volatility and β=1.22, the stock exhibits high sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. The tenth stock on our list is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR). TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating. The firm noted that […]
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return
Why Arrowhead Pharmaceuticals Is Drawing Investor Attention Now Arrowhead Pharmaceuticals (ARWR) is back on many watchlists after a sharp total return over the past 3 months and the past year. This has prompted fresh questions about how its RNAi pipeline and current valuation line up. See our latest analysis for Arrowhead Pharmaceuticals. With the share price at US$64.52, Arrowhead has given investors a 64.47% 90 day share price return and a 218.77% 1 year total shareholder return. This...
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arrowhead (ARWR) to $78 from $81 and keeps an Equal Weight rating on the shares. Broad pipeline execution continues with multiple readouts expected later this year, including key Phase 3 SHTG data in Q3, the analyst tells investors in a research note. the firm added that while early familial chylomicronemia syndrome launch trends are promising, meaningful sales are not expected in 2026.Valentine's Day Sale - 70% OffUnlock hedge fund-level data an
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript
In fact, the recent months have included some of the more significant achievements in Arrowhead's history. First, on November 18, 2025, Arrowhead received its first regulatory approval and began the next phase of growth as a commercial company marketing its own medicines. This approval was supported by clinical data from the Phase III PALISADE study in adults with either clinically diagnosed or genetically confirmed FCS.
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ...
Arrowhead Pharmaceuticals Inc (ARWR) reports robust revenue growth and strategic progress in its cardiometabolic and CNS pipelines, despite rising R&D expenses.
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) highlighted a series of regulatory, commercial, clinical, and financing milestones in its fiscal 2026 first-quarter earnings call, covering the period ended December 31, 2025. Management emphasized the U.S. approval and launch of its first commercial product,
Arrowhead Research: Fiscal Q1 Earnings Snapshot
ARWR) on Thursday reported fiscal first-quarter net income of $30.8 million, after reporting a loss in the same period a year earlier. The Pasadena, California-based company said it had net income of 22 cents per share. The results fell short of Wall Street expectations.
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial
Arrowhead Pharmaceuticals recently reported dosing the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, an RNAi drug candidate designed to silence both PCSK9 and APOC3 to address atherosclerotic cardiovascular disease caused by mixed hyperlipidemia. This marks the first time a single RNA interference molecule has been advanced into human testing to target two genes simultaneously, highlighting Arrowhead’s TRiM platform as an important platform-level development in cardiometabolic drug...
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million
This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its pipeline.
Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data
We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. Arrowhead Pharmaceuticals, Inc. is among the best high growth stocks. TheFly reported on January 13 that Piper Sandler lifted its price target on ARWR to $110 from $100, and reiterated an Overweight rating. The firm mentioned the new release of Redemplo […]
Frequently Asked Questions
Common investor questions about Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $63.59. The RSI (14-day) is at 43.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $81.36 implies 27.9% upside from current levels. Volatility is moderate at 37.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Arrowhead Pharmaceuticals, Inc. (ARWR): The trailing P/E ratio is 39.88, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is -14.85, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 15.42. Price-to-Sales is 8.19. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering ARWR, the consensus price target is $81.36. This represents a 27.9% upside from the current price of $63.59. The range spans from a low target of $35.00 to a high target of $110.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Arrowhead Pharmaceuticals, Inc. (ARWR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Arrowhead Pharmaceuticals, Inc. (ARWR) investors include: 1. Moderate volatility (37.7% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 124.07) which could pressure margins in a rising rate environment. 3. Elevated short interest (11.1% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Arrowhead Pharmaceuticals, Inc.'s (ARWR) current debt and financial health profile: Total debt stands at $698.16M. The debt-to-equity ratio is 124.07, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 3.38, indicating strong short-term liquidity. The quick ratio is 3.26. The company holds $914.71M in cash and equivalents. Free cash flow is positive at $170.73M, providing a cushion for debt servicing and shareholder returns.